Recruiting

Telerehabilitation

Sponsor:

VA Office of Research and Development

Code:

NCT05179408

Conditions

Lung Cancer

Cancer Survivors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Targeted-telerehabilitation

Waitlist

Study Details

Brief summary:

Lung cancer is the second-most commonly diagnosed cancer among U.S. Veterans. Substantial advances have been made in early detection through screening and treatment. The longevity of Veterans following lung cancer diagnosis and treatment has increased. Following treatment however, many Veterans experience increased symptom burden, particularly in shortness of breath, fatigue, and fear/anxiety about lung cancer, and impairments in physical and psychosocial functioning. Rehabilitation services are needed to address these survivorship challenges. This study will evaluate multi-targeted telerehabilitation with Veterans following lung cancer treatment, with goals to reduce symptom burden, improve physical and psychosocial function, and enhance health-related quality of life. This research will also develop the career of a physician researcher to acquire expertise in rehabilitation for many Veteran survivors of lung and other cancers.

Conditions

Lung Cancer

Cancer Survivors

Study ID

NCT05179408

Start date

Jan 12, 2026

Status verified date

Jan, 2026

Completion date

Mar 30, 2027

Anticipated

Primary completion date

Mar 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult Veterans with a history of stage I-III A/B lung cancer, and
  • Completed curative intent therapy (i.e., lung cancer resection surgery, definitive radiation, or concurrent chemoradiation) within 1-6 months

Exclusion Criteria:

  • Adult Veterans with any comorbid conditions that preclude participation in exercise and telerehabilitation:
  • Orthopedic conditions (e.g., bilateral below-knee amputation), or
  • Severe cardiopulmonary disease (e.g., unstable arrhythmias including ventricular tachycardia, heart failure with systolic ejection fraction < 25%, chronic hypoxemia needing > 5 L/min oxygen supplementation at rest), or
  • Inability to follow directions or provide informed consent (e.g., moderate to severe dementia), or
  • Enrolled in hospice, or
  • With an estimated life expectancy of < 6 months

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Targeted telerehabilitation

Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/endurance; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)

active comparator: Waitlist

8-week waiting period prior to participating in targeted telerehabilitation

Interventions

Targeted-telerehabilitation

Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/stept count; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)

Waitlist

8-week waiting period prior to targeted telerehabilitation

Primary outcome measure

  • Health-related quality of life (HRQL) [ Time Frame: Difference in changes in HRQL between baseline and end-of-intervention (8 weeks) ]

Central Contacts and Locations

Central contacts

Locations

Rocky Mountain Regional VA Medical Center, Aurora, CO

Recruiting

Aurora, Colorado, United States, 80045-7211

Contacts

Principal Investigator:

Duc M. Ha, MD MAS

More Information

Sponsor

VA Office of Research and Development

Last update posted

Jan 27, 2026

Last verified

Jan, 2026

Keywords

  • Rehabilitation
  • Exercise training
  • Mindfulness training
  • Survivorship
  • US Veterans
  • Telemedicine

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by VA Office of Research and Development on 2026-01-27.